{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"condition":["colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/47501"],"location":["China"],"study_start_month":["9"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Phase IB clinical study on the tolerance, safety and efficacy of darafenib, trametinib combined with irinotecan and cetuximab in advanced colorectal cancer with BRAF mutation","description":"Interventions: experimental group:Darafenitumertinib plus iritiniconcetuximab\nPrimary outcome(s): Maximum tolerated dose\nStudy Design: Cross-sectional","dates":{"creation":"2022-09-15"},"accession":"47501","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2200063316"]}}